We considered three such drugs that are currently in at least phase 2 trial for patients with relapsed myeloma—venetoclax [for t(11;14)],8 MEK inhibitor [for KRAS/NRAS‐mutated myeloma]9 or combined BRAF and MEK inhibitors [for BRAF‐mutated myeloma].10 Here, KRAS is linked to plasma cell myeloma.